[Role of bronchospasm in development of bronchial obstruction in chronic bronchitis].
OBJECTIVE
To clarify the role of bronchospasm in impairment of bronchial permeability in chronic bronchitis.


METHODS
Lung capacity (LC), forced lung capacity (FLC), forced expiration volume for 1 second (FEV1), FEV1/LC%, peak volume rate (PVS), maximal volume expiration rate (MVER) at the level of 25, 50 and 75% of LC were measured in 62 patients with chronic obstructive bronchitis before and after inhalation of 1 dose of berotec and 1 dose of atrovent.


RESULTS
Bronchospasm was present in 42% of the patients, being the only cause of obstruction in 5% of patients. Other reasons added in 37%. Bronchospasm contribution to obstruction reached 21-40, 41-80, 81-100% in 5, 10 and 27% of patients, respectively.


CONCLUSIONS
An important role of bronchospasm in development of bronchial obstruction in chronic bronchitis is proved.
V B
VB
Nefedov
E A
EA
Shergina
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D001986:Bronchial Spasm / Q000150:complications* / Q000503:physiopathology; D001991:Bronchitis / Q000209:etiology* / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage; D002908:Chronic Disease; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests; D012307:Risk Factors
D001993:Bronchodilator Agents; D005280:Fenoterol; D009241:Ipratropium